CAMBRIDGE, Massachusetts, USA & COPENHAGEN, Denmark — March 5, 2026
Hemab Therapeutics, a clinical-stage biotechnology company focused on developing innovative treatments for severe bleeding disorders, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to sutacimig, its investigational biologic therapy designed to prevent bleeding episodes in patients with Glanzmann Thrombasthenia (GT). The designation marks an important regulatory milestone and underscores the therapy’s potential to address a major unmet medical need for patients suffering from this rare and debilitating genetic bleeding disorder. Breakthrough Therapy Designation is reserved for medicines that show preliminary clinical evidence of substantial improvement over existing treatments, enabling accelerated development timelines and increased regulatory interaction with the FDA.
FDA Breakthrough Therapy Status Accelerates Development
The Breakthrough Therapy Designation (BTD) program was established by the FDA to expedite the development of promising treatments for serious or life-threatening diseases. By granting this status to sutacimig, the FDA acknowledges the therapy’s potential to provide significant clinical benefit compared with current treatment options available to patients with Glanzmann thrombasthenia.
Under the Breakthrough Therapy pathway, Hemab Therapeutics will receive enhanced regulatory support, including closer collaboration with FDA experts and guidance throughout the clinical development process. This may allow the company to accelerate clinical trials, streamline regulatory submissions, and potentially bring the therapy to patients more quickly.
The designation was supported by a comprehensive clinical data package, including positive findings from the Phase 2 multiple-ascending-dose portion of Hemab’s Phase 1/2 clinical trial evaluating sutacimig. These results demonstrated clinically meaningful reductions in bleeding episodes, including severe events that normally require high-intensity medical interventions such as recombinant factor VIIa therapy, platelet transfusions, or emergency medical procedures.
Advertisement
In addition to Breakthrough Therapy Designation, sutacimig has also received Fast Track Designation and Orphan Drug Designation from the FDA, further reinforcing the regulatory priority placed on advancing new therapies for rare diseases.
Novel Antibody Mechanism Targets Rare Bleeding Disorder
Sutacimig is a subcutaneously administered bispecific antibody designed to enhance the body’s natural clotting mechanism. The therapy works by binding to endogenous Factor VIIa while simultaneously targeting TLT-1 receptors on activated platelets, enabling the accumulation of clotting factors at the site of vascular injury. This mechanism helps facilitate the formation of a stable hemostatic plug that can stop bleeding more effectively.
The investigational therapy is being developed as a first-in-class prophylactic treatment for Glanzmann thrombasthenia, a rare inherited disorder caused by defects in platelet glycoprotein receptors responsible for blood clot formation. Individuals with the condition often experience frequent and sometimes life-threatening bleeding episodes, including nosebleeds, gastrointestinal bleeding, and prolonged bleeding following injuries or medical procedures.
Current treatment options for GT are limited and typically involve reactive interventions such as platelet transfusions or recombinant clotting factors, which are administered only after bleeding episodes occur. There are currently no approved preventive therapies designed specifically to reduce bleeding risk in these patients, highlighting the urgent need for new treatment strategies.
By targeting the underlying mechanisms of platelet-mediated clot formation, sutacimig may provide a proactive approach to managing bleeding risk, potentially transforming the treatment landscape for patients living with Glanzmann thrombasthenia.
Rare Disease Burden Highlights Urgent Medical Need
Although considered rare, Glanzmann thrombasthenia has a profound impact on the lives of affected individuals. Data from the international Glanzmann’s 360 natural history study, which analyzed patient experiences globally, revealed that 88% of participants reported at least one bleeding episode in the previous week, and 65% required a hospital visit due to bleeding complications within six months.
These frequent bleeding episodes can significantly disrupt everyday life. Many patients report missed school or work, limitations on social activities, and psychological stress associated with unpredictable bleeding events. For families managing the disease, access to effective preventive treatments could dramatically improve both quality of life and long-term health outcomes.
Hemab Therapeutics is building a broader pipeline of therapies aimed at addressing serious coagulation disorders with high unmet medical need, including Factor VII deficiency and von Willebrand disease. The company’s strategy focuses on developing prophylactic biologic therapies that prevent bleeding events before they occur, rather than relying solely on reactive treatments.
With the FDA’s Breakthrough Therapy Designation now in place, sutacimig’s development program may progress more rapidly through the clinical and regulatory pathway, bringing the possibility of a first-in-class preventive therapy for Glanzmann thrombasthenia closer to reality.
z
Source: Hemab Therapeutics press release
